Z31.440 Insurance Policy Changes

ICD-10 Z31.440 is officially defined as "Encounter of male for testing for genetic disease carrier status for procreative management." code Z31.440 is referenced in 7 tracked payer policy changes from Excellus BlueCross BlueShield, Aetna, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code Z31.440 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Excellus BlueCross BlueShield · Effective Jul 16, 2026High impact
Genetic Testing for Cystic Fibrosis 2.02.17
The July 16, 2026 update made expanded CFTR testing (CPT 81223) medically necessary when standard variant testing is insufficient to establish a diagnosis or assess reproductive risk, and when results will impact clinical or reproductive decision-making. Common-variant CF genetic testing is medically appropriate when results will impact clinical care, the test is performed by a CLIA-certified laboratory, and a listed circumstance applies, such as diagnostic testing for people with symptoms of CF and a negative sweat test, carrier testing for people with a family history of CF, or prenatal testing when both parents have a diagnosis of CF.
Aetna · Identified Oct 4, 2026Medium impact
Genetic Testing (CPB 0140, reviewed 2026-08-18)
Aetna covers genetic testing only when the criteria for the specific condition are met, and it considers testing outside those criteria experimental, investigational, or unproven, including testing for Parkinson disease, essential tremor, coronary artery disease (except testing for familial hypercholesterolemia), and type 2 diabetes other than MODY. Multi-gene panels for inherited cancers are covered only for members with a personal or family history of a related cancer when more than one inherited cancer syndrome could explain the presentation and the panel is more efficient than separate tests, and genetic testing for inherited cancers is a once-in-a-lifetime benefit. Expanded carrier screening for people who are pregnant or planning a pregnancy is covered when the panel includes cystic fibrosis, spinal muscular atrophy, and/or hemoglobinopathies, unless previously performed, and the results will be used in managing the pregnancy or for family planning; whole exome or whole genome sequencing is covered for an unexplained congenital or neurodevelopmental disorder when its listed criteria are met, and whole genome sequencing after a non-diagnostic whole exome test is considered not medically necessary.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Genetic Testing for FMR1 Variants (including Fragile X Syndrome)
Genetic testing for FMR1 variants may be considered medically necessary for individuals with characteristics of fragile X syndrome or a fragile X-associated disorder, and for individuals with a personal or family history of fragile X syndrome who are seeking reproductive counseling. Genetic testing for FMR1 variants is investigational for all other uses. Cytogenetic testing is no longer considered an acceptable diagnostic method according to American College of Medical Genetics and Genomics standards.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Genetic Testing for Alpha-1 Antitrypsin Deficiency
Genetic testing for alpha-1 antitrypsin deficiency may be considered medically necessary when the individual is suspected of having the condition because of clinical factors, or may be at high risk because of a first-degree relative with AAT deficiency. It may also be considered medically necessary when the individual has a serum alpha1-antitrypsin level in the range of severe deficiency. Genetic testing is considered investigational in all other situations.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Genetic Testing for PTEN Hamartoma Tumor Syndrome
Genetic testing for PTEN may be considered medically necessary to confirm a diagnosis when an individual has clinical signs of a PTEN hamartoma tumor syndrome. Targeted testing for a PTEN familial variant may be considered medically necessary in a first-degree relative of a proband with a known PTEN pathogenic variant, and all other genetic testing for PTEN is considered investigational. The 07/31/2026 update changed the policy description and removed ICD-9 diagnosis codes, and the policy statements are unchanged.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Genetic Testing for Duchenne and Becker Muscular Dystrophy
Blue Cross Blue Shield of Mississippi policy A.2.04.86 treats DMD gene variant testing as medically necessary in a male with signs and symptoms of a dystrophinopathy to confirm the diagnosis and direct treatment. It also covers testing for at-risk female relatives to confirm or exclude the need for cardiac surveillance, preconception testing for a woman considering a pregnancy, and testing for at-risk male offspring to confirm or exclude the need for medical and cardiac surveillance. Genetic testing for DMD gene variants is considered investigational in all other situations.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Genetic Testing for Hereditary Hemochromatosis
Genetic testing for HFE gene variants may be considered medically necessary in individuals with abnormal serum iron indices indicating iron overload, or in individuals with a family history of hemochromatosis in a first-degree relative. Genetic testing for hereditary hemochromatosis for screening of the general population is considered investigational. The 09/21/2026 update changed the policy number from L.2.04.460 to A.2.04.80, updated the policy description, and removed ICD-9 diagnosis codes from the Code Reference, and the policy statements are unchanged.

Watch Z31.440

Get one email when a payer policy names Z31.440, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code Z31.440?

There are 7 tracked policy changes affecting code Z31.440, including updates from Excellus BlueCross BlueShield, Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code Z31.440?

Payers that have issued tracked updates for code Z31.440 include: Excellus BlueCross BlueShield, Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code Z31.440 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code Z31.440. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code Z31.440?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Genetic Testing for Cystic Fibrosis 2.02.17

Genetic Testing (CPB 0140, reviewed 2026-08-18)

Genetic Testing for FMR1 Variants (including Fragile X Syndrome)

Genetic Testing for Alpha-1 Antitrypsin Deficiency

Genetic Testing for PTEN Hamartoma Tumor Syndrome

Genetic Testing for Duchenne and Becker Muscular Dystrophy

Genetic Testing for Hereditary Hemochromatosis

What insurance policy changes affect code Z31.440?

Which payers have updated policy for code Z31.440?

How do I get notified when code Z31.440 policy changes?

Why do payers change policies for code Z31.440?